Abstract:Aggregation of amyloid β-protein (Aβ) into β-sheet-rich plaques is a general feature of Alzheimer's disease (AD). Homeostasis dysregulation of Cu2+ mediates Aβ to form high cytotoxic aggregates, which causes cell damage by generation of reactive oxygen species (ROS). To improve the inhibitory potency and explore the multifaceted functions of our previously designed decapeptide, RTHLVFFARK-NH2 (RK10), we have herein reformulated the decapeptide into its d-enantiomer, rk10, and the effects of chirality on Aβ aggregation, Cu2+-mediated Aβ aggregations, and aggregate-remodeling effects were investigated. The results revealed the following: (1) The d-enantiomer presented enhanced inhibitory potency on Aβ fibrillogenesis in comparison to RK10; rk10 and RK10 increased the cell viability from 60% to 91% and 71%, respectively, at an equimolar concentration to Aβ. (2) The enantiomers were chemically equivalent to Cu2+ chelation, ROS suppression and oxidative damage rescue. (3) The d-enantiomer exhibited higher performance to inhibit Cu2+-mediated Aβ aggregation, and more significantly attenuated the cytotoxicity caused by Aβ42-Cu2+ complex than RK10. Cell viability was rescued from 51% to 89% and 74% by coincubating with rk10 and RK10 at 50 μM, respectively. Intracellular ROS levels generated by Aβ42 and Aβ42-Cu2+ species were also remarkably decreased by treating with rk10. (4) The enantiomers could remodel mature Aβ42-Cu2+ aggregates by Cu2+ chelation, and rk10 showed higher performance than RK10, as evidenced by the enhanced cell viability from 57% to 86% by RK10 and to 96% by rk10. The d-enantiomer also showed higher ability than RK10 on protecting the disrupted species from reaggregation. Taken together, D-chiral derivatization of the decapeptide resulted in a potent multifunctional agent in inhibiting Cu2+-mediated Aβ aggregation and remodeling mature Aβ-Cu2+ species. To the best of our knowledge, this is the first investigation on the chirality effect of a multifunctional peptide inhibitor on Cu2+-mediated Aβ aggregation and on the remodeling effect of mature Aβ-Cu2+ aggregates. The work provides new insights into the critical role of chirality in the multifaceted functions of peptide inhibitors against amyloid formation and its toxicity.

Toward the Mode of Action of the Clinical Stage All-d-Enantiomeric Peptide RD2 on Aβ42 Aggregation

The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology

Molecular Integrative Analysis of the Inhibitory Effects of Dipeptides on Amyloid β Peptide 1–42 Polymerization

Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers

Energy Landscapes of the Monomer and Dimer of the Alzheimer’s Peptide Aβ(1–28)

D-Enantiomeric RTHLVFFARK-NH2: A Potent Multifunctional Decapeptide Inhibiting Cu2+-Mediated Amyloid Β-Protein Aggregation and Remodeling Cu2+-Mediated Amyloid Β Aggregates

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Pharmacokinetic Properties of a Novel d-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers

In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer’s Disease

A Comprehensive Insight into the Mechanisms of Dopamine in Disrupting Aβ Protofibrils and Inhibiting Aβ Aggregation

Inhibition of Alzheimer’s Amyloid Toxicity with a Tricyclic Pyrone Molecule in Vitro and in Vivo

Study on the Efficiency and Interaction Mechanism of a Decapeptide Inhibitor of Β-Amyloid Aggregation.

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization

Structural Reorganization Mechanism of the Aβ42 Fibril Mediated by N-Substituted Oligopyrrolamide ADH-353

Rational Design of a Cocktail of Inhibitors Against Aβ Aggregation.

An 11-mer Synthetic Peptide Suppressing Aggregation of Aβ25-35 and Resolving Its Aggregated Form Improves Test Performance in an Aβ25-35-Induced Alzheimer's Mouse Model

Dissecting the Inhibitory Mechanism of the Αb-Crystallin Domain Against Aβ42 Aggregation and Its Effect on Aβ42 Protofibrils: A Molecular Dynamics Simulation Study

Cooperative dissolution of peptidomimetic vesicles and amyloid beta fibrils